Adenylate Cyclase Catalytic Domain (rCatACT)

Adenylate Cyclase Catalytic Domain (rCatACT), Recombinant from Bordetella pertussis

Catalog #



964-100 50 μg $200
964-110 200 μg $600
964-120 1 mg $2600
964-130 > 5 mg Inquire


Recombinant CatACT is supplied in 0.05M MES (pH 7), 0.05M NaCl, 50% glycerol at a desired concentration of 0.1 to 0.5 mg/ml.

Adenylate cyclase (ACT) is an essential virulence factor of B. pertussis, which functions by inhibiting neutrophil defenses. The cell-invasive ACT toxin is synthesized from the cyaA gene. The gene product is a bifunctional protein of 1706 amino acids (177 kD) exhibiting both adenylate cyclase and hemolysin activities. The homolysin domain of ACT shares sequence homology with other members of the RTX toxin family, including the E. coli hemolysin, which lacks adenylate cyclase enzymatic activity. The 400 amino acids of the N-terminal of ACT (termed Cat-ACT) comprise the catalytic domain and are unique to ACT.

A DNA fragment encoding the first 400 amino acids of the cyaA gene is PCR amplified from B. pertussis BP338 and cloned into a pET vector allowing the direct expression of non-tagged protein. The recombinant CatACT protein (43 kD) is expressed in E. coli strain BL21(DE3) and purified from inclusion bodies.

Store at -20°C. To insure uniformity, it is recommended that the CatACT suspension be swirled or gently mixed prior to use.

Protein Content
Protein concentration was determined by Bradford assay method using bovine serum albumin as standard.

>95% by SDS-PAGE.

Quality control documentation of each lot is provided with shipment.